<DOC>
	<DOCNO>NCT02802280</DOCNO>
	<brief_summary>Hypothesis : In addition liver deleterious effect , Chronic Hepatitis C ( CHC ) cause change organs highlight increase cardiovascular risk ( CVR ) accelerate atherosclerosis , whose consequence may persist even heal infection new antiviral treatment . This major impact health system . Obtaining Sustained Virological Response ( SVR ) free Interferon ( IFN ) antiviral treatment probably able reverse , least partially , increase vascular risk induce Hepatitis C virus ( HCV ) perhaps ultimately reverse subclinical atherosclerosis . Aims : To study presence early-subclinical atherosclerotic disease ( endothelial dysfunction subclinical atherosclerosis ) patient CHC evaluate influence treatment short medium term CVR derive . Studying issue patient establish atherosclerotic disease .</brief_summary>
	<brief_title>Endothelial Dysfunction Subclinical Atheromatosis Chronic HCV Infection . Response DAA Agents .</brief_title>
	<detailed_description>Design : Prospective interventional study . Patients method : Tracked population 80 patient CHC ( estimate fibrosis F2-F3 ) , An evaluation CVR perform determine biomarkers endothelial activation macrophage activation , measure flow-mediated vasodilation atherosclerotic damage . All evaluation take place prior ( baseline ) antiviral treatment . Particularly , determination perform immediately 3 , 12 24 month end antiviral treatment . In order improve diagnostic accuracy term discriminate liver damage associate Non Alcoholic Fatty Liver Disease ( NAFLD ) HCV infection , investigator use owl-liver® technique patient treatment . Sample size : Considering primary endpoint flow-mediated vasodilation ( FMD ) , data report FMD 7.6 ± 2.4 % healthy subject 5.1 ± 2.2 % subject risk factor ( Dalli et al Rev Esp Cardiol 2002 ; 55 : 928-35 ) . Assuming SD correlation coefficient 0.3 two measurement , 80 patient need detect change 1 % vasodilation output 90 % significance level 5 % . Variables task : Task 1 . Assessment endothelial function . 1 . -Vasodilation mediate ultrasound brachial flow rate increase brachial artery diameter ( d2 ) compare baseline ( d1 ) ischemia time ( 300 mmHg ) 4 minute ( FMD = ( d2-d1 ) / d1 ( x 100 ) . 2 . -Endothelial function biomarkers : ICAM-1 , VCAM-1 , E-selectin , P-selectin , MCP-1 , angiopoietin-2 , sTWEAK ADMA . 3 . - Macrophage activation biomarkers : Gal-3BP , sCD163 sCD14 . Task 2 . Assessment atherosclerotic damage . Common carotid , internal carotid carotid bulb ( bilateral ) explore ultrasound . The image electronically store DICOM format . The analyzed parameter : 1. cIMT ( Carotid intima medium thickness carotid intima-media thickness ) define distance interface carotid lumen arterial intima interface medium adventitia distal arterial wall . They measure back wall free-plaque area common carotid ( cIMT CC ) carotid bulb ( cIMT -B ) , internal carotid ( cIMT -CI ) . 2 . Presence carotid plaque territory . Plaque define follow Mannheim criterion . 3 . Presence atherosclerotic plaque : distinguish focal diffuse thicken . In focal plate area , maximum thickness Gray Scale Median ( GSM ) quantify . In diffuse thickening ( IMT &gt; 1.5 mm ) GSM quantify . Task 3 . Assessment vascular risk . Classic emerge vascular risk assessment . 1 . -Study classic risk factor : REGICOR Framingham Score table . Fatty Liver Index exclude confirm NASH ( BMI , waist circumference , triglyceride GGT ) . Metabolic syndrome detect NCEP-ATPIII . 2 . - Study emerge vascular risk factor , include proinflammatory factor . In way , investigator analyze plasma level hcPCR , homocysteine , Lp ( ) , pentraxin 3 , SAA , oxidize LDL , PON1 , PCSK9 elevate plasma level von Willebrand factor factor ( VWF ) 3 . - Qualitative lipoprotein change : total concentration lipoprotein ( VLDL , LDL , HDL ) determine well composition ( total cholesterol , triglyceride , phospholipid , protein , apolipoprotein B , lipoprotein ratio / total triglyceride mass VLDL , LDL HDL , number VLDL , LDL HDL , cholesterol molecule per particle triglyceride molecule per particle ) . 4 . - Insulin resistance HOMA . 5 . -HbA1c 6 . - Rx Thorax . h ) -ECG QTc interval measurement .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>HCV infect patient ( aged 1875 yr ) Naive failure previous treatment Liver fibrosis F2F3 Fibroscan/liver biopsy Accept study sign CI Known cardiovascular disease Does meet criterion VIH viral coinfection Hepatocarcinoma Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>endothelial dysfunction</keyword>
</DOC>